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ABSTRACT
Background: Eighty percent of patients treated medical-
ly for gastroesophageal reflux disease relapse after treat-
ment. Many of these patients require indefinite treatment
with omeprazole to prevent recurrence. Nissen fundopli-
cation has been shown to be effective, safe and cost effec-
tive in the management of gastroesophageal reflux dis-
ease. We suggest a treatment algorithm, which encour-
ages early surgical intervention in cases of recurrent
esophagitis after a previously successful two-month course
of omeprazole.
Methods: We have offered laparoscopic Nissen fundo-
plication since 1993. Patients who received Nissen fun-
doplication since 1990 were asked to report return to
baseline activity, medications, and lifestyle changes.
Concurrent chart review of patients treated with omepra-
zole was conducted to analyze cost.
Results: Patients receiving laparoscopic Nissen fundopli-
cation were discharged significantly sooner and spent sig-
nificantly less time convalescing when compared to those
who underwent open Nissen fundoplication.
Laparoscopic Nissen fundoplication became cost effective
at 1.5 to 2 years when compared to omeprazole.
Conclusion: Based on cost analysis, patient satisfaction,
acceptable complication rate, and efficient use of time and
resources, we recommend laparoscopic Nissen fundopli-
cation as the appropriate treatment in patients who devel-
op recurrent esophagitis after a two-month treatment with
omeprazole.
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INTRODUCTION
Medical management of gastroesophageal reflux disease
(GERD) with H-2 blockers, antacids, and omeprazole is
effective, but as many as 80% of patients managed med-
ically relapse when omeprazole is stopped. Further,
medical management is expensive, and many patients
are now placed on lifetime maintenance doses of
omeprazole to prevent the complications of reflux.
Nissen fundoplication is an effective treatment for GERD,
and multiple studies comparing open Nissen fundoplica-
tion (ONF) to laparoscopic Nissen fundoplication (LNF)
show equivalent short-term control of symptoms. No
studies in the literature combine cost analysis with
patient satisfaction and outcome. We questioned
whether LNF was cost effective compared to current
medical management. We conducted a retrospective
chart review and survey of hospital stay, convalescence,
control of symptoms, and length of medical management
concurrent with a cost analysis of medical management,
ONF, and LNF for the treatment of GERD. We then
developed a treatment algorithm, which emphasizes
early surgical management in patients who relapse after
an initial successful two-month treatment with omepra-
zole.
MATERIALS AND METHODS
Laparoscopic Nissen fundoplication has been performed
at William Beaumont Army Medical Center since 1993.
The charts of all patients who underwent laparoscopic
and open Nissen fundoplication since 1990 were
reviewed through 1995. Patients were asked to report
medications required before and after surgery, time to
return to baseline activity, and if they would recommend
the procedure to others. Patients under 18 years of age
were excluded. Thirty-five patients underwent a Nissen
fundoplication during the study interval. Sixteen patients
who received LNF and nine who received ONF were
available for interview.
Concurrent review of 46 charts was undertaken of
patients with GERD managed with omeprazole. The
only data recorded was amount and duration of medica-
tion directed at controlling GERD symptoms. Cost analy-
sis data was collected through the Procurement Offices
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of Pharmacy and Surgery as well as the Department of
Treasury and Third Party Collections. An assumption was
made that initial work-up and follow-up costs for both
medical and surgical patients were equal. The cost of
medical management includes follow-up esophagogas-
troduodenostoscopy, office visits, and emergency depart-
ment visits for non-cardiac chest pain.
1 Statistical analy-
sis was performed using student's t-test. P values <0.05
were considered significant.
RESULTS
Average hospital stay was 7.38 days in the open group
and 2.70 days in the laparoscopic group (P<0.05) (Figure
1). The convalescence time, calculated as time from sur-
gery until return to work, was 35.3 days in the open
group and 17.90 days in the laparoscopic group (P<0.05)
(Figure 2). All patients in both groups would recom-
mend the procedure to others. Patients in both groups
averaged 24.9 months of H-2 blocker treatment and 10.75
weeks of omeprazole treatment. The annual cost of 40
mg of daily omeprazole at government rate is $1,500.71.
The annual cost of 20 mg of daily omeprazole with 10 mg
of cisapride three times daily is $1,154.67. Cost of LNF is
2,276.58 based on 1995 reimbursement rates. One
patient in the LNF group experienced return of symptoms
at six weeks, which resolved with subsequent ONF. One
patient in the LNF group experienced gas bloat syn-
Figure 1. Mean hospital days after LNF (2.70) and ONF (7.38)
P<.05.
drome, which was improving, but not resolved, at one
year. One patient in the LNF group required occasional
cimetidine postoperatively. One patient in the open
group acquired postoperative pneumonia, which
resolved with treatment. No patients reported lifestyle
modifications postoperatively, and there were no deaths.
Cost effectiveness was achieved at two years in patients
treated with 40 mg of omeprazole daily.
Figure 2. Mean number of days from surgery until return to
work in the LNF (17.9) and ONF (35.3) P<0.05.
Figure 3. Cost of civilian and military LNF compared to medical
therapy with 40 mg omeprazole and 20 mg omeprazole with 10
mg cisapride three times a day over a 5 year period.
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Figure 4. Recommended preoperative work-up prior to LNF.
DISCUSSION
A large prospective randomized study has shown that
ONF is superior to medical management with H-2 recep-
tor antagonists in healing esophagitis.
2 Unfortunately,
this study predated wide-spread use of omeprazole in
this country, and, to date, no prospective randomized
trial has compared proton pump antagonists to surgery
for control of esophagitis. Several studies have shown
that an appropriate maintenance therapy for prevention
of recurrent esophagitis is 10-20 mg omeprazole every-
day.
3,
4 This regimen requires a compliant patient, fre-
quent follow-up, and substantial cost. Multiple studies
have shown omeprazole in doses of 20-40 mg daily
results in complete resolution of esophagitis within 60
days;
5-
7 however, cessation of omeprazole results in
recurrent esophagitis in 80% of patients.
5 Patients who
do not resolve their esophagitis or symptoms on 20-40
mg daily of omeprazole in 60 days warrant evaluation for
other non-GERD causes for their symptoms. The litera-
ture is clear that medical therapy will resolve most if not
all symptoms from GERD. However, this approach
requires indefinite medical therapy. Expense with this
approach includes follow-up visits for prescription refill,
the medication itself and emergency department and car-
Figure 5. Recommended treatment algorithm for surgical treat-
ment of GERD.
diac care unit visits for atypical chest pain. Despite hav-
ing these issues clearly defined in the literature, a 1995
New England Journal of Medicine article and editorial
stated that preferred management for GERD was long-
term (>4 years) omeprazole and cisapride.
8,
9 Further, the
long-term implications of omeprazole treatment remain
unclear. No gastric cancer has occurred in humans
attributable to omeprazole to date, but the implications
of hypergastrinemia, corpus gastritis, argyrophil cell
hyperplasia, and atrophie gastritis remain unclear.
10,1
1 In
our institution, treatment with surgery became cost effec-
tive at 1.5 years in patients treated with 20 mg of omepra-
zole daily and 10 mg cisapride three times daily. Cost
effectiveness was achieved at two years in patients treat-
ed with 40 mg omeprazole daily (Figure 3). No signifi-
cant long-term complications were observed in the sur-
gical groups, and complications were not noted in the
medical group.
CONCLUSION
Despite small numbers in our study, we feel that laparo-
scopic Nissen fundoplication is the logical treatment for
GERD in patients who fail a 2-month trial of omeprazole
treatment and meet criteria for fundoplication (Figure
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4). We suggest, based on patient satisfaction, cost analy-
sis, acceptable complication rate, and efficient use of time
and resources, that laparoscopic Nissen fundoplication is
the appropriate treatment in patients who develop recur-
rent esophagitis after two months of treatment with
omeprazole (Figure 5).
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